TY - JOUR
T1 - Serotype Distribution and Disease Severity in Adults Hospitalized with Streptococcus pneumoniae Infection, Bristol and Bath, UK, 2006-2022
AU - Hyams, Catherine
AU - Challen, Robert
AU - Hettle, David
AU - Amin-Chowdhury, Zahin
AU - Grimes, Charli
AU - Ruffino, Gabriella
AU - Conway, Rauri
AU - Heath, Robyn
AU - North, Paul
AU - Malin, Adam
AU - Maskell, Nick A.
AU - Williams, Philip
AU - Martin Williams, O.
AU - Ladhani, Shamez N.
AU - Danon, Leon
AU - Finn, Adam
N1 - Publisher Copyright:
© 2023 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2023/10
Y1 - 2023/10
N2 - Ongoing surveillance after pneumococcal conjugate vaccination (PCV) deployment is essential to inform policy decisions and monitor serotype replacement. We report serotype and disease severity trends in 3,719 adults hospitalized for pneumococcal disease in Bristol and Bath, United Kingdom, during 2006-2022. Of those cases, 1,686 were invasive pneumococcal disease (IPD); 1,501 (89.0%) had a known serotype. IPD decreased during the early COVID-19 pandemic but during 2022 gradually returned to prepandemic levels. Disease severity changed throughout this period: CURB65 severity scores and inpatient deaths decreased and ICU admissions increased. PCV7 and PCV13 serotype IPD decreased from 2006-2009 to 2021-2022. However, residual PCV13 serotype IPD remained, representing 21.7% of 2021-2022 cases, indicating that major adult PCV serotype disease still occurs despite 17 years of pediatric PCV use. Percentages of serotype 3 and 8 IPD increased, and 19F and 19A reemerged. In 2020-2022, a total of 68.2% IPD cases were potentially covered by PCV20.
AB - Ongoing surveillance after pneumococcal conjugate vaccination (PCV) deployment is essential to inform policy decisions and monitor serotype replacement. We report serotype and disease severity trends in 3,719 adults hospitalized for pneumococcal disease in Bristol and Bath, United Kingdom, during 2006-2022. Of those cases, 1,686 were invasive pneumococcal disease (IPD); 1,501 (89.0%) had a known serotype. IPD decreased during the early COVID-19 pandemic but during 2022 gradually returned to prepandemic levels. Disease severity changed throughout this period: CURB65 severity scores and inpatient deaths decreased and ICU admissions increased. PCV7 and PCV13 serotype IPD decreased from 2006-2009 to 2021-2022. However, residual PCV13 serotype IPD remained, representing 21.7% of 2021-2022 cases, indicating that major adult PCV serotype disease still occurs despite 17 years of pediatric PCV use. Percentages of serotype 3 and 8 IPD increased, and 19F and 19A reemerged. In 2020-2022, a total of 68.2% IPD cases were potentially covered by PCV20.
UR - https://www.scopus.com/pages/publications/85171956134
U2 - 10.3201/eid2910.230519
DO - 10.3201/eid2910.230519
M3 - Article
C2 - 37735739
AN - SCOPUS:85171956134
SN - 1080-6040
VL - 29
SP - 1953
EP - 1964
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 10
ER -
